| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| CapMed Division | | | | | | | | 0.4 |
| Pharmaceutical Contract Services | | | | | | | | 30.1 |
| Total revenues [+] | 98.3 | 84.0 | 75.2 | 72.7 | 69.1 | 47.3 | 40.3 | 30.5 |
| Services | 79.0 | 68.0 | 62.7 | 57.4 | | | | |
| Reimbursements | 19.3 | 16.0 | 12.5 | 15.3 | | | | |
| Revenue growth [+] | 17.0% | 11.7% | 3.4% | 5.2% | 46.3% | 17.4% | 32.1% | 2.7% |
| CapMed Division | | | | | | | | 223.7% |
| Pharmaceutical Contract Services | | | | | | | | 1.8% |
| Cost of goods sold [+] | 67.9 | 58.2 | 52.0 | 51.0 | 32.4 | 21.9 | 19.6 | 18.3 |
| Cost of services | 48.6 | 42.2 | 39.6 | 35.6 | | | | |
| Reimbursable costs | 19.3 | 16.0 | 12.5 | 15.3 | | | | |
| Gross profit | 30.4 | 25.8 | 23.2 | 21.8 | 36.7 | 25.4 | 20.6 | 12.2 |
| Gross margin | 30.9% | 30.7% | 30.8% | 29.9% | 53.1% | 53.7% | 51.2% | 39.9% |
| Selling, general and administrative [+] | 22.3 | 18.9 | 17.5 | 15.5 | 14.9 | 10.7 | 9.4 | 9.7 |
| Sales and marketing | 10.7 | 8.7 | 9.0 | 8.1 | 7.9 | 5.0 | 4.3 | 4.8 |
| General and administrative | 11.6 | 10.2 | 8.4 | 7.4 | 7.0 | 5.7 | 5.1 | 5.0 |
| Other operating expenses | 0.5 | 0.6 | 0.6 | 0.5 | 13.3 | 14.1 | 11.1 | 6.8 |
| EBITDA [+] | 12.8 | 10.8 | 8.5 | 8.5 | 10.7 | 2.9 | 2.2 | -2.0 |
| EBITDA growth | 18.4% | 27.0% | -0.1% | -20.7% | 275.1% | 31.4% | -207.8% | -160.1% |
| EBITDA margin | 13.0% | 12.9% | 11.3% | 11.7% | 15.5% | 6.1% | 5.4% | -6.6% |
| Depreciation | 4.7 | 3.9 | 2.8 | 2.7 | 2.3 | 2.3 | 2.0 | 2.3 |
| EBITA | 8.1 | 6.9 | 5.7 | 5.8 | 8.5 | 0.5 | 0.1 | -4.3 |
| EBITA margin | 8.2% | 8.2% | 7.6% | 8.0% | 12.3% | 1.1% | 0.4% | -14.2% |
| Amortization of intangibles | 0.5 | 0.6 | 0.6 | | | | | |
| EBIT [+] | 7.5 | 6.3 | 5.1 | 5.8 | 8.5 | 0.5 | 0.1 | -4.3 |
| EBIT growth | 20.5% | 23.4% | -12.8% | -31.5% | 1500.0% | 263.0% | -103.4% | -370.2% |
| EBIT margin | 7.7% | 7.4% | 6.7% | 8.0% | 12.3% | 1.1% | 0.4% | -14.2% |
| Non-recurring items | 1.0 | 1.9 | 0.7 | 1.1 | | | | |
| Interest income, net [+] | -0.1 | 0.0 | 0.0 | 0.0 | 0.4 | 0.6 | 0.5 | 0.1 |
| Interest expense | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.7 | 0.6 | 0.2 |
| Other income (expense), net | | | | | | 0.0 | 0.1 | |
| Pre-tax income | 6.4 | 4.3 | 4.3 | 4.7 | 8.9 | 1.2 | 0.8 | -4.3 |
| Income taxes | 2.7 | 1.5 | 1.6 | 1.8 | 3.1 | -2.1 | -1.2 | -1.7 |
| Tax rate | 41.8% | 35.4% | 36.4% | 37.3% | 34.9% | | | 40.1% |
| Earnings from continuing ops | 3.7 | 2.8 | 2.8 | 3.0 | 5.8 | 3.3 | 2.0 | -2.5 |
| Earnings from discontinued ops | | | | | -3.0 | -1.0 | -1.0 | |
| Net income | 3.7 | 2.8 | 2.8 | 3.0 | 2.8 | 2.3 | 1.0 | -2.5 |
| Net margin | 3.8% | 3.3% | 3.7% | 4.1% | 4.0% | 4.9% | 2.5% | -8.3% |
| |
| Basic EPS [+] | $0.24 | $0.18 | $0.18 | $0.21 | $0.42 | $0.29 | $0.18 | ($0.23) |
| Growth | 33.4% | -2.4% | -11.2% | -51.0% | 46.3% | 64.1% | -176.6% | -360.9% |
| Diluted EPS [+] | $0.23 | $0.17 | $0.17 | $0.20 | $0.40 | $0.26 | $0.16 | ($0.23) |
| Growth | 32.8% | -1.8% | -11.5% | -51.0% | 52.6% | 64.8% | -169.5% | -360.9% |
| |
| Shares outstanding (basic) [+] | 15.6 | 15.7 | 15.0 | 14.4 | 13.8 | 11.6 | 11.2 | 11.1 |
| Growth | -0.2% | 4.1% | 4.7% | 4.4% | 18.4% | 3.5% | 0.9% | 2.8% |
| Shares outstanding (diluted) [+] | 16.5 | 16.4 | 15.9 | 15.1 | 14.5 | 12.7 | 12.4 | 11.1 |
| Growth | 0.3% | 3.5% | 5.1% | 4.4% | 13.5% | 3.1% | 11.2% | 2.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |